Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China

被引：0
|
作者：
Haijing Guan
Chunping Wang
Zhigang Zhao
Sheng Han
机构：
[1] Capital Medical University,Department of Pharmacy, Beijing Tiantan Hospital
[2] Peking University,China Center for Health Economic Research
[3] Peking University,International Research Center for Medicinal Administration
[4] Peking University,School of Pharmaceutical Sciences
来源：
Advances in Therapy | 2022年 / 39卷
关键词：
Donafenib; Cost-effectiveness; Partitioned survival model; Unresectable hepatocellular carcinoma; China;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3334 / 3346
页数：12
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China
    Li, Wei
    Wan, Li
    BMJ OPEN, 2023, 13 (09):
  • [22] Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
    Zhou, Ting
    Wang, Xintian
    Cao, Yingdan
    Yang, Lan
    Wang, Zijing
    Ma, Aixia
    Li, Hongchao
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [23] Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
    Ting Zhou
    Xintian Wang
    Yingdan Cao
    Lan Yang
    Zijing Wang
    Aixia Ma
    Hongchao Li
    BMC Health Services Research, 22
  • [24] Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states
    Wen, Feng
    Zheng, Hanrui
    Zhang, Pengfei
    Liao, Weiting
    Zhou, Kexun
    Li, Qiu
    LIVER INTERNATIONAL, 2021, 41 (05) : 1097 - 1104
  • [25] Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wen, Feng
    Huang, Peng
    Wu, Qiuji
    Yang, Yang
    Li, Qiu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 469 - 469
  • [26] Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China
    Zhao, Jingping
    Jiang, Kaida
    Li, Qingwei
    Zhang, Yanlei
    Cheng, Yan
    Lin, Ziyi
    Xuan, Jianwei
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (05) : 439 - 446
  • [27] COST-EFFECTIVENESS OF OLANZAPINE IN THE FIRST-LINE TREATMENT OF SCHIZOPHRENIA IN CHINA
    Zhao, J.
    Jiang, K.
    Li, Q.
    Zhang, Y. L.
    Cheng, Y.
    Lin, Z.
    Xuan, J.
    VALUE IN HEALTH, 2018, 21 : S76 - S77
  • [28] Donafenib as a first-line monotherapy for advanced hepatocellular carcinoma
    Zhang, Bo -Han
    Cai, Yun-Shi
    Jiang, Li
    Yang, Jia-Yin
    HEPATOBILIARY SURGERY AND NUTRITION, 2021, 10 (05) : 737 - 740
  • [29] Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
    Masnoon Saiyed
    Joshua Byrnes
    Tushar Srivastava
    Paul Scuffham
    Martin Downes
    Clinical Drug Investigation, 2020, 40 : 1167 - 1176
  • [30] Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
    Saiyed, Masnoon
    Byrnes, Joshua
    Srivastava, Tushar
    Scuffham, Paul
    Downes, Martin
    CLINICAL DRUG INVESTIGATION, 2020, 40 (12) : 1167 - 1176
12345